[
  {
    "ts": "2025-11-18T15:33:00+00:00",
    "headline": "Cervical Dystonia Research Analysis Report 2025-2035: Market Sees Intense Competition as Ipsen, Merz, and AbbVie Advance Therapies Through Strategic Expansions",
    "summary": "The global cervical dystonia market is thriving, driven by increased disease prevalence, advancements in neuromodulation techniques, and heightened awareness of movement disorders. Key factors include the widespread adoption of botulinum toxin therapies and deep brain stimulation for refractory cases, along with innovations in drug formulations. While barriers such as diagnosis delays and treatment cost persist, strategic efforts by industry leaders like Ipsen and AbbVie are shaping market dynam",
    "url": "https://finance.yahoo.com/news/cervical-dystonia-research-analysis-report-153300521.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "7cdfda54-4044-379e-b932-3f0ed94825e9",
      "content": {
        "id": "7cdfda54-4044-379e-b932-3f0ed94825e9",
        "contentType": "STORY",
        "title": "Cervical Dystonia Research Analysis Report 2025-2035: Market Sees Intense Competition as Ipsen, Merz, and AbbVie Advance Therapies Through Strategic Expansions",
        "description": "",
        "summary": "The global cervical dystonia market is thriving, driven by increased disease prevalence, advancements in neuromodulation techniques, and heightened awareness of movement disorders. Key factors include the widespread adoption of botulinum toxin therapies and deep brain stimulation for refractory cases, along with innovations in drug formulations. While barriers such as diagnosis delays and treatment cost persist, strategic efforts by industry leaders like Ipsen and AbbVie are shaping market dynam",
        "pubDate": "2025-11-18T15:33:00Z",
        "displayTime": "2025-11-18T15:33:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc",
          "originalWidth": 480,
          "originalHeight": 58,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_MlAqEncKPaKK77zrkRGmQ--~B/aD01ODt3PTQ4MDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc.cf.webp",
              "width": 480,
              "height": 58,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/caWFqk489OEmv3xI33JamQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/cervical-dystonia-research-analysis-report-153300521.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/cervical-dystonia-research-analysis-report-153300521.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "IPN.PA"
            },
            {
              "symbol": "ABBV"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-18T14:37:00+00:00",
    "headline": "Here's How Neuroscience Drugs Aided AbbVie's Top-line Growth in Q3",
    "summary": "ABBV's neuroscience drugs drive strong Q3 momentum, with rising Botox Therapeutic sales, migraine therapies and new PD treatments fueling growth.",
    "url": "https://finance.yahoo.com/news/heres-neuroscience-drugs-aided-abbvies-143700828.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "c9e8ac52-48bc-3904-90f7-1459204d2244",
      "content": {
        "id": "c9e8ac52-48bc-3904-90f7-1459204d2244",
        "contentType": "STORY",
        "title": "Here's How Neuroscience Drugs Aided AbbVie's Top-line Growth in Q3",
        "description": "",
        "summary": "ABBV's neuroscience drugs drive strong Q3 momentum, with rising Botox Therapeutic sales, migraine therapies and new PD treatments fueling growth.",
        "pubDate": "2025-11-18T14:37:00Z",
        "displayTime": "2025-11-18T14:37:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/dbd916198e87314e1ef238f8179e6227",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/OQG3.5Wd9P9R69q2rhm9rA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/dbd916198e87314e1ef238f8179e6227.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/pBlncPVBhEXpjxtBDlEOsg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/dbd916198e87314e1ef238f8179e6227.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/heres-neuroscience-drugs-aided-abbvies-143700828.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/heres-neuroscience-drugs-aided-abbvies-143700828.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABBV"
            },
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]